Posner increased his holding by 2.29% to a total of $2.27. Following Posner’s last ALQA Buy transaction on May 20, 2015, the stock climbed by 0.6%.
Based on Alliqua`s latest earnings report from March 31, the company posted quarterly revenue of $2.11M and GAAP net loss of $7.66M. In comparison, last year the company earned revenue of $1.04M and had a GAAP net loss of $5.95M. The company has a one year high of $6.55 and a one year low of $3.70. Currently, Alliqua has an average volume of 6,138.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $9.00, reflecting a -45.1% downside. Starting in June 2014, ALQA received 10 Buy ratings in a row. Four different firms, including Chardan Capital and Northland Securities, currently also have a Buy rating on the stock.
Looking at blogger coverage of ALQA, there is a 100% Bullish tendency on the stock, in relation to a 67% average bullish tendency within the Healthcare sector.
Over the last 3 months, the insider sentiment on Alliqua has been neutral based on 19 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.
Alliqua BioMedical Inc is a biomedical company providing wound care solutions. It is also engaged in contract manufacturing.